supp.fit

Zeaxanthin and Lutein: study protocols

70 study groups took Zeaxanthin together with Lutein. These are the doses the studies gave. They are not a recommendation.

Zeaxanthin: what the research found →

Dose per serving from research: Zeaxanthin

70 study groups in 47 studies say how much Zeaxanthin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 mg to 2.5 mg, 66% of 70 study groups.

Daily doseStudy groups
500 mcg or less
4
500 mcg to 1 mg
8
1 mg to 2.5 mg
46
2.5 mg to 5 mg
4
5 mg to 10 mg
6
over 10 mg
2

Dose per serving from research: Lutein

70 study groups in 47 studies say how much Lutein participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 74% of 70 study groups.

Daily doseStudy groups
2.5 mg or less
2
2.5 mg to 5 mg
4
5 mg to 10 mg
52
10 mg to 25 mg
12

Commonly used together

41 of 70 study groups took Zeaxanthin and Lutein with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Meso-Zeaxanthin
16
Omega-3 Fatty Acids
12
Docosahexaenoic Acid
7
Vitamin C
7
Vitamin E
7
Zinc
6
Astaxanthin
3
Copper
3

70 study groups

Study
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
2 mg10 mg5 years—
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
2014 · lutein/zeaxanthin · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified
2 mg10 mg1789 days—
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18
2019 · Lutein and zeaxanthin addition · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye
2 mg10 mg5 years—
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
2 mg10 mg5 years—
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified
2 mg10 mg1789 days—
No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18
2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye
2 mg10 mg5 years—
Supplemental Retinal Carotenoids Enhance Memory in Healthy Individuals with Low Levels of Macular Pigment in A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2018 · active group · Healthy individuals with low macular pigment levels; mean age 45.42 years, 51.6% male
2 mg10 mg1 year45
Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults
2017 · active supplement group · Healthy adults aged 18–30 years, college students, without a stated diagnosed condition
2 mg10 mg1 year37
Effects of Astaxanthin, Lutein, and Zeaxanthin on Eye-Hand Coordination and Smooth-Pursuit Eye Movement after Visual Display Terminal Operation in Healthy Subjects: A Randomized, Double-Blind Placebo-Controlled Intergroup Trial
2023 · active group · Healthy Japanese males and females aged 20–60 years who routinely used visual display terminals or played video games
2 mg10 mg8 weeks32
Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration
2015 · lutein (10 mg) + zeaxanthin (10 mg) · Adults aged over 50 with clinically diagnosed early age-related macular degeneration
10 mg10 mg2 years28
Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial
2012 · 10 mg/d lutein plus 10 mg/d zeaxanthin · People with early age-related macular degeneration; age range and sex not reported
10 mg10 mg48 weeks27
Increases in plasma lutein through supplementation are correlated with increases in physical activity and reductions in sedentary time in older adults
2014 · Lutein · Adults aged 55–80 who were not obese and did not meet physical activity guidelines
900 mcg21 mg4 weeks19
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · Lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
2 mg10 mg5 years—
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
2 mg10 mg12 weeks96
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
2 mg10 mg24 weeks40
Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
2022 · active group · Cognitively healthy adults aged 65 years and older
2 mg10 mg2 years30
Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula
2020 · LM group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration
3 mg15 mg26 weeks29
Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula
2020 · PV group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration
2 mg10 mg26 weeks20
Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year
2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years
1 mg10 mg1 year15
Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up
2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years
4 mg20 mg26 weeks15
Beneficial Effects of Micronutrient Supplementation in Restoring the Altered Microbiota and Gut-Retina Axis in Patients with Neovascular Age-Related Macular Degeneration-A Randomized Clinical Trial
2024 · intervention group · Adults with neovascular age-related macular degeneration; mean age 77.8 years
2 mg10 mg26 weeks15
Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study
2012 · treated group · Patients with age-related macular degeneration; age and sex not stated
1 mg10 mg2 years—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
2 mg10 mg5 years—
Effect of Dietary Supplementation with Lutein, Zeaxanthin, and Elderberries on Dry Eye Disease (DED) and Immunity: A Randomized Controlled Trial
2024 · intervention group · Adults aged 18 years or older with dry eye symptoms
1 mg6 mg20 days—
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast
2014 · L+Z · Young, healthy subjects; age and sex not specified
2 mg10 mg1 year57
A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency
2014 · Multi · Healthy adults aged 18–32 years
26 mg8 mg120 days25
Night Vision and Carotenoids (NVC): A Randomized Placebo Controlled Clinical Trial on Effects of Carotenoid Supplementation on Night Vision in Older Adults
2021 · treatment group · Older US veterans with difficulty seeing at night, without overt ocular disease; mean age 62.7 years
14 mg7 mg26 weeks24
The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial
2014 · Lutein Egg · Healthy adults aged 18 years and older with macular pigment optical density below 0.55
137 mcg921 mcg90 days20
The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial
2014 · Zeaxanthin Egg · Healthy adults aged 18 years and older with macular pigment optical density below 0.55
487 mcg174 mcg90 days20
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 1 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
2 mg20 mg8 weeks10
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 2 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
2 mg10 mg8 weeks10
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 3 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
2 mg3 mg8 weeks10
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 1 · Adults with or without age-related macular degeneration; age and sex not reported
2 mg20 mg8 weeks—
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 2 · Adults with or without age-related macular degeneration; age and sex not reported
2 mg10 mg8 weeks—
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 3 · Adults with or without age-related macular degeneration; age and sex not reported
2 mg3 mg8 weeks—
Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration
2013 · lutein plus zeaxanthin (LZ) · Chinese patients older than 50 years with early age-related macular degeneration
10 mg10 mg48 weeks—
Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study
2013 · kale group · Adults with non-exudative age-related macular degeneration; age range and sex not reported
3 mg10 mg4 weeks—
Effect of Long-Term Xanthophyll and Anthocyanin Supplementation on Lutein and Zeaxanthin Serum Concentrations and Macular Pigment Optical Density in Postmenopausal Women
2018 · Group X—xanthophylls · Postmenopausal women aged 50–70 years
2 mg6 mg240 days—
Effect of Long-Term Xanthophyll and Anthocyanin Supplementation on Lutein and Zeaxanthin Serum Concentrations and Macular Pigment Optical Density in Postmenopausal Women
2018 · Group X+A—anthocyanines and xanthophylls · Postmenopausal women aged 50–70 years
2 mg6 mg240 days—
Systemic Effects of Prenatal Carotenoid Supplementation in the Mother and her Child: The Lutein and Zeaxanthin in Pregnancy (L-ZIP) Randomized Trial -Report Number 1
2023 · Carotenoid group · First-trimester pregnant subjects
2 mg10 mg240 days—
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
2 mg10 mg1 year50
Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study
2024 · LZ group · Children aged 5–12 years, male and female
2 mg10 mg180 days40
Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids
2014 · low-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants
96 mcg6 mg6 weeks29
Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration
2012 · 10 mg/day lutein plus 10 mg/day zeaxanthin · Adults aged 50–79 with early age-related macular degeneration
10 mg10 mg48 weeks27
Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids
2014 · high-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants
192 mcg12 mg6 weeks26
Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973
2011 · 8 mg Zx plus 9 mg lutein · Patients with mild-to-moderate age-related macular degeneration, mean age 74.9 years; 57 men and 3 women across the study
8 mg9 mg1 year25
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 2 · People with early age-related macular degeneration; age and sex not stated
2 mg10 mg1 year21
Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements
2015 · FloraGLO group · Healthy Japanese adults aged 20 years and older, without ocular or systemic pathologies
960 mcg10.5 mg26 weeks18
Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements
2015 · XanMax group · Healthy Japanese adults aged 20 years and older, without ocular or systemic pathologies
1.29 mg10.4 mg26 weeks18
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 1 · People with early age-related macular degeneration; age and sex not stated
2 mg20 mg1 year17
Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial
2021 · LZ supplement group · Healthy men and women aged 45–65 years with normal macular condition and no signs of drusen or early AMD
4 mg6 mg90 days15
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 3 · People with early age-related macular degeneration; age and sex not stated
2 mg3 mg1 year14
Supplementation with all three macular carotenoids: response, stability, and safety
2011 · intervention (I group) · healthy adults; age and sex not specified
1.2 mg5.9 mg26 weeks—
The impact of macular pigment augmentation on visual performance using different carotenoid formulations
2012 · group 1 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified
2 mg20 mg26 weeks—
The impact of macular pigment augmentation on visual performance using different carotenoid formulations
2012 · group 2 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified
2 mg10 mg26 weeks—
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
1 mg10 mg1 year—
Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial
2015 · lutein (10 mg)+zeaxanthin (10 mg) · Patients with early age-related macular degeneration
10 mg10 mg2 years—
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
2015 · Macushield, Alzheimer's disease patients · Adults with Alzheimer's disease; age range and sex not stated
2 mg10 mg26 weeks—
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
2015 · Macushield, age-similar control subjects · Age-similar control subjects; age range and sex not stated
2 mg10 mg26 weeks—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 1 · People with early age-related macular degeneration; age and sex not specified
860 mcg20 mg3 years—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 2 · People with early age-related macular degeneration; age and sex not specified
2 mg10 mg3 years—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 3 · People with early age-related macular degeneration; age and sex not specified
2 mg3 mg3 years—
The effects of lutein and zeaxanthin on resting state functional connectivity in older Caucasian adults: a randomized controlled trial
2020 · Lutein and zeaxanthin supplement · Community-dwelling older adults, mean age 72 years
2 mg10 mg1 year—
Lack of a Synergistic Effect on Cardiometabolic and Redox Markers in a Dietary Supplementation with Anthocyanins and Xanthophylls in Postmenopausal Women
2019 · Group X (xanthophylls) · Women aged 50–70 years, postmenopausal for more than two years, with BMI 25–33 kg/m²
2 mg6 mg243 days—
Lack of a Synergistic Effect on Cardiometabolic and Redox Markers in a Dietary Supplementation with Anthocyanins and Xanthophylls in Postmenopausal Women
2019 · Group A+X (anthocyanins + xanthophylls) · Women aged 50–70 years, postmenopausal for more than two years, with BMI 25–33 kg/m²
2 mg6 mg243 days—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein plus zeaxanthin · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
2 mg10 mg5 years—
Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
2013 · D2 (twice daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified
2 mg20 mg1 year55
Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
2013 · D1 (once daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified
1 mg10 mg1 year50
Lutein Complex Supplementation Increases Ocular Blood Flow Biomarkers in Healthy Subjects
2019 · lutein phytochemicals complex · Healthy women, mean age 36.8 ± 12.1 years
2 mg10 mg3 weeks16
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
2 mg10 mg5 years—